Cencora (NYSE:COR) Given New $405.00 Price Target at Leerink Partners

Posted by Brian Himes on Nov 5th, 2026

Cencora (NYSE:COR – Get Free Report) had its price objective hoisted by Leerink Partners from $388.00 to $405.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s price objective suggests a potential upside of 19.15% from the company’s previous close.

COR has been the subject of several other research reports. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $330.00 target price on shares of Cencora in a report on Tuesday, September 8th. Wells Fargo & Company increased their price target on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded Cencora from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, October 6th. Finally, JPMorgan Chase & Co. boosted their price target on Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $369.44.

Check Out Our Latest Analysis on COR

Cencora Trading Down 4.0%

COR stock traded down $14.10 during midday trading on Thursday, hitting $339.90. 1,256,625 shares of the company’s stock were exchanged, compared to its average volume of 1,467,095. Cencora has a one year low of $244.82 and a one year high of $377.54. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. The company has a market cap of $64.86 billion, a PE ratio of 25.23, a price-to-earnings-growth ratio of 1.74 and a beta of 0.58. The stock’s fifty day moving average price is $324.60 and its 200-day moving average price is $317.44.

Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.58 by $0.08. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company had revenue of $88.35 billion during the quarter, compared to the consensus estimate of $87.95 billion. During the same quarter in the prior year, the firm earned $3.84 earnings per share. The firm’s revenue was up 5.5% compared to the same quarter last year. Research analysts predict that Cencora will post 17.88 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the transaction, the executive vice president directly owned 19,455 shares of the company’s stock, valued at $6,305,754.60. This represents a 36.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.38% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cencora

A number of hedge funds and other institutional investors have recently modified their holdings of COR. Lido Advisors LLC raised its stake in Cencora by 8.9% in the 3rd quarter. Lido Advisors LLC now owns 8,760 shares of the company’s stock worth $2,630,000 after purchasing an additional 715 shares in the last quarter. Keybank National Association OH boosted its holdings in Cencora by 3.6% in the 3rd quarter. Keybank National Association OH now owns 18,206 shares of the company’s stock valued at $5,466,000 after purchasing an additional 630 shares during the period. D Orazio & Associates Inc. bought a new stake in Cencora in the 3rd quarter valued at about $206,000. 71 West Capital Partners boosted its holdings in Cencora by 5.6% in the 3rd quarter. 71 West Capital Partners now owns 1,805 shares of the company’s stock valued at $542,000 after purchasing an additional 95 shares during the period. Finally, Beutel Goodman & Co Ltd. grew its position in shares of Cencora by 29.1% during the 3rd quarter. Beutel Goodman & Co Ltd. now owns 658,222 shares of the company’s stock worth $197,631,000 after purchasing an additional 148,544 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Key Stories Impacting Cencora

Here are the key news stories impacting Cencora this week:

Positive Sentiment: Fiscal Q4 adjusted EPS was $4.66, above the $4.58 consensus, while revenue of $88.4 billion also topped estimates and rose 5.5% year over year. Specialty-drug demand and expanding margins supported the results. Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand
Positive Sentiment: Cencora set a fiscal 2027 adjusted EPS outlook of $19.40–$19.75; coverage characterized the forecast as an improvement. This signals continued expected earnings growth. Cencora outlines fiscal 2027 EPS outlook
Positive Sentiment: The company raised its quarterly dividend 10% to $0.66 per share, a modest positive for shareholder returns. Cencora dividend announcement
Neutral Sentiment: Cencora is reorganizing its reporting structure into two segments to improve focus and visibility. The strategic change could support execution, but its effect on results remains to be seen. Cencora announces new organizational and reporting structure
Negative Sentiment: The earnings call also highlighted headwinds alongside specialty growth. That caution may be weighing on the shares despite the earnings beat; the supplied coverage does not specify the headwinds’ expected financial impact. Cencora earnings call highlights specialty growth and headwinds

Cencora Company Profile

(Get Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.